Wrapping up Q1 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - specialty stocks, including Teleflex (NYSE: TFX) and its peers.

The surgical equipment and consumables industry provides tools, devices, and disposable products essential for surgeries and medical procedures. These companies therefore benefit from relatively consistent demand, driven by the ongoing need for medical interventions, recurring revenue from consumables, and long-term contracts with hospitals and healthcare providers. However, the high costs of R&D and regulatory compliance, coupled with intense competition and pricing pressures from cost-conscious customers, can constrain profitability. Over the next few years, tailwinds include aging populations, which tend to need surgical interventions at higher rates. The increasing integration of AI and robotics into surgical procedures could also create opportunities for differentiation and innovation. However, the industry faces headwinds including potential supply chain vulnerabilities, evolving regulatory requirements, and more widespread efforts to make healthcare less costly.

The 4 surgical equipment & consumables - specialty stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 2.7% while next quarter’s revenue guidance was in line.

Luckily, surgical equipment & consumables - specialty stocks have performed well with share prices up 11.5% on average since the latest earnings results.

Teleflex (NYSE: TFX)

With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE: TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.

Teleflex reported revenues of $548.3 million, up 32.3% year on year. This print exceeded analysts’ expectations by 2.8%. Despite the top-line beat, it was still a mixed quarter for the company with a beat of analysts’ EPS estimates but a significant miss of analysts’ full-year EPS guidance estimates.

"Our first-quarter performance reflects disciplined execution and meaningful progress against our transformation plan," said Stuart Randle, Teleflex's Interim President and Chief Executive Officer.

Teleflex scored the fastest revenue growth of the whole group. Unsurprisingly, the stock is up 3.8% since reporting and currently trades at $127.86.

Is now the time to buy Teleflex? Access our full analysis of the earnings results here, it’s free.

Best Q1: Intuitive Surgical (NASDAQ: ISRG)

Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ: ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties.

Intuitive Surgical reported revenues of $2.77 billion, up 23% year on year, outperforming analysts’ expectations by 5.8%. The business had a stunning quarter with a solid beat of analysts’ revenue and EPS estimates.

Intuitive Surgical pulled off the biggest analyst estimate beat among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 7.4% since reporting. It currently trades at $418.00.

Is now the time to buy Intuitive Surgical? Access our full analysis of the earnings results here, it’s free.

LeMaitre (NASDAQ: LMAT)

Founded in 1983 and named after a pioneering vascular surgeon, LeMaitre Vascular (NASDAQGM:LMAT) develops and manufactures specialized medical devices used by vascular surgeons to treat peripheral vascular disease and other circulatory conditions.

LeMaitre reported revenues of $66.55 million, up 11.2% year on year, in line with analysts’ expectations. Still, its results were good as it locked in an impressive beat of analysts’ EPS guidance for next quarter estimates and a solid beat of analysts’ full-year EPS guidance estimates.

LeMaitre delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 16.7% since the results and currently trades at $93.33.

Read our full analysis of LeMaitre’s results here.

Integra LifeSciences (NASDAQ: IART)

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Integra LifeSciences reported revenues of $391.9 million, up 2.4% year on year. This result topped analysts’ expectations by 2.6%. Overall, it was a strong quarter as it also recorded a solid beat of analysts’ full-year EPS guidance estimates.

Integra LifeSciences pulled off the highest full-year guidance raise but had the slowest revenue growth among its peers. The stock is up 66.5% since reporting and currently trades at $17.73.

Read our full, actionable report on Integra LifeSciences here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand-wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.